We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
0.125 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
1
Market Cap
5.68M

Momentum Score

…

Polomar Health Services, Inc. operates as a retail compounding pharmacy in the United States. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded with vitamin B-12 and/or metformin; Tofacitinib, it treats rheumatoid arthritis by inhibiting JAK to reduce inflammation and pain; Semaglutide GLP-1, which regulates blood sugar, appetite, and weight in diabetes management; and compounded erectile dysfunction medications inhalable sildenafil. It also includes dermatological formulations for the treatment of acne, alopecia areata, basal cell carcinoma, Becker's nevus, vitiligo, and other skin conditions. In addition, it provides prescription fulfillment services for third party web based tele-health platforms. The company is based in Los Angeles, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.07
Low
0.12
High
52 Week Price Range
0.05
Low
0.80
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on PMHS (ticker PMHS.US, Pink) is limited; the company's core business and financials are not clearly disclosed in standard filings. Because of sparse disclosure, long-term growth drivers cannot be reliably identified, though investors may find exposure to small-cap upside if the company later provides transparent operations and filings.
The most important investment risks are severe information and liquidity risk due to thin pink-sheet listing and scarce filings, heightened regulatory and governance uncertainty, and the possibility of significant volatility or loss of capital.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.12
Dividend Yield
-
Revenue TTM
3.17M
Revenue Per Share
0.11
Gross Profit TTM
1.94M
Debt / Equity
-0.01
ROE
-257.88%
Net Debt
-0.12M
ROCE
863.13%
Diluted EPS TTM
-0.35

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -10.70M -1.34M -0.42M -0.18M -0.17M
Net income -10.70M -1.34M -0.42M -0.18M -0.17M
Selling general administrative 10.94M 1.28M 0.27M 0.22M 0.04M
Selling and marketing expenses 0.07M 0.05M - - -
Gross profit 0.46M 0.03M 0.04M 0.03M -
Reconciled depreciation 9.77M 0.26M 0.01M - -
Ebit -10.55M -1.30M -0.42M -0.18M -0.17M
Ebitda -0.78M -1.04M -0.15M -0.18M -0.13M
Depreciation and amortization 9.77M 0.26M 0.27M 0.18M 0.04M
Operating income -10.55M -1.30M -0.27M -0.18M -0.04M
Other operating expenses 11.20M 1.36M 0.27M 0.22M 0.04M
Interest expense 0.15M 0.04M 0.00M - -
Interest income - - 0.00M 0.00M -
Net interest income -0.15M -0.04M -0.00M 0.00M -
Total revenue 0.65M 0.06M 0.04M 0.03M -
Total operating expenses 11.01M 1.33M 0.27M 0.22M 0.04M
Cost of revenue 0.19M 0.03M 0.00M 0.00M -
Total other income expense net -0.15M -0.04M -0.15M 0.00M -0.13M
Net income from continuing ops -10.70M -1.34M -0.59M -0.18M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 0.39M 9.95M 0.00M 0.26M -
Intangible assets 0.25M 0.25M 0.00M - -
Other current assets - - - 0.01M -
Total liab 1.61M 0.01M 0.01M 0.07M 0.04M
Total stockholder equity -1.22M 9.94M -0.01M 0.19M -0.04M
Other current liab 0.91M 1.30M - 0.07M 0.00M
Common stock 0.03M 0.03M 0.11M 0.11M 0.00M
Capital stock 0.03M 0.03M 0.11M 0.11M -
Retained earnings -13.61M -2.91M -1.40M -0.98M -0.80M
Cash 0.13M 0.01M 0.00M 0.23M -
Total current liabilities 1.61M 1.34M 0.01M 0.07M 0.04M
Current deferred revenue 0.30M - - -0.07M -0.00M
Net debt -0.12M 0.04M -0.00M -0.16M 0.03M
Short term debt 0.01M 0.03M 0.06M 0.07M 0.03M
Short long term debt 0.90M 1.14M - - -
Short long term debt total 0.01M 0.05M 0.08M 0.07M 0.03M
Other stockholder equity 12.36M 24.30M 1.28M 0.98M 1.43M
Total current assets 0.32M 0.08M 0.00M 0.26M -
Net receivables 0.10M 0.00M 0.00M 0.03M -
Inventory 0.09M 0.07M 0.00M - -
Accounts payable 0.39M 0.16M 0.01M 0.01M 0.00M
Accumulated other comprehensive income - - - 0.04M -0.63M
Non currrent assets other -0.24M 9.53M - - -
Non current assets total 0.07M 9.87M 0.09M 0.00M -
Capital lease obligations 0.01M 0.05M 0.08M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.09M 0.00M - -
Total cashflows from investing activities - -0.09M - - -
Net borrowings 0.52M 1.14M -0.07M 0.04M -
Total cash from financing activities 0.52M 1.11M 0.15M 0.27M 0.03M
Net income -10.70M -1.34M -0.42M -0.18M -0.17M
Change in cash 0.13M -0.00M -0.23M 0.23M -
Begin period cash flow 0.01M 0.01M 0.23M 0.00M -
End period cash flow 0.13M 0.01M 0.00M 0.23M -
Total cash from operating activities -0.40M -1.02M -0.37M -0.04M -0.03M
Issuance of capital stock - - 0.22M 0.23M -
Depreciation 9.77M 0.26M 0.01M - -
Other cashflows from investing activities - - -0.00M - -
Change to inventory -0.02M -0.07M -0.00M -0.00M -
Change to account receivables -0.10M -0.00M 0.01M -0.03M -
Other cashflows from financing activities 0.52M 1.11M - - 0.03M
Capital expenditures 0.00M 0.09M 0.00M 0.00M 0.00M
Change in working capital 0.40M 0.06M 0.02M -0.03M 0.00M
Stock based compensation 0.13M - 0.00M 0.17M -
Other non cash items 0.40M 0.06M 0.02M 0.20M 0.13M
Free cash flow -0.40M -1.11M -0.37M -0.04M -0.03M

Peer Comparison*

Sector: Healthcare Industry: Pharmaceutical Retailers

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PMHS
PMHS
-
-%
0.12 - - 1.79 1.73 1.98 -0.03
JDHIF
JD Health International Inc
-
-%
4.79 15.09 15.11 0.18 1.52 0.59 6.26
ALBBY
Alibaba Health Information Technology Limited
-
-%
7.84 34.43 19.84 0.29 3.79 1.73 25.72
RADLY
Raia Drogasil SA ADR
-0.08
2.96%
2.62 22.35 24.69 0.14 4.59 0.90 10.93
ALBHF
Alibaba Health Information Technology Limited
-
-%
0.33 17.35 16.69 0.16 2.11 0.89 13.04

Profile*

PMHS

Polomar Health Services, Inc. operates as a retail compounding pharmacy in the United States. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded with vitamin B-12 and/or metformin; Tofacitinib, it treats rheumatoid arthritis by inhibiting JAK to reduce inflammation and pain; Semaglutide GLP-1, which regulates blood sugar, appetite, and weight in diabetes management; and compounded erectile dysfunction medications inhalable sildenafil. It also includes dermatological formulations for the treatment of acne, alopecia areata, basal cell carcinoma, Becker's nevus, vitiligo, and other skin conditions. In addition, it provides prescription fulfillment services for third party web based tele-health platforms. The company is based in Los Angeles, California.

10940 Wilshire Boulevard, Los Angeles, CA, United States, 90024

212 245 3413

6

Name Title Year Born
Mr. Terrence M. Tierney J.D. President & Interim CEO 1962
Mr. Charlie Lin C.M.A., CPA Treasurer 1971
Mr. George Ronald Hornig J.D. Executive Chairman of the Board 1954
Mr. Douglas J. Beck CPA CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer 1961
Mr. Timothy M. Papp Secretary & General Counsel NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…